Steven P. Piccoli
Steven P. Piccoli has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- John Michael Sauer
Denali Therapeutics Institution
2 shared publications - Karen J. Quadrini
Prothena Biosciences Inc, Brisbane, CA 94005, USA
2 shared publications - Lauren F. Stevenson
Immunologix Laboratories
2 shared publications - Nicholas M. P. King
Critical Path Institute Tucson Arizona USA
2 shared publications - Yan G. Ni
Passage Bio
2 shared publications - Alok Pandey
PBL Assay Science
1 shared publication
Latest Publications
- Open Access
- 30 September 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-4
Why is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?
- 30 September 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-4
Open AccessWhy is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?
- 12 August 2025
- Published by Taylor & Francis in Bioanalysis
- p. 1-2
Special consideration: commentary on the 2025 FDA Bioanalytical Method Validation for Biomarkers
- 12 August 2025
- Published by Taylor & Francis in Bioanalysis
- p. 1-2
Special consideration: commentary on the 2025 FDA Bioanalytical Method Validation for Biomarkers
- 4 January 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (5) , 1272-1283
Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury
Two observational studies were conducted to support an initiative to qualify translational kidney safety biomarkers as clinical drug development tools that identify tubular injury prior to changes in estimated glomerular filtration rate (eGFR). Normal healthy volunteers provided three morning spot urine collections over 4 weeks. Patients undergoing surgical resection and intrathoracic cisplatin for malignant pleural mesothelioma provided urine samples pre‐ and postoperatively at 4, 8, and 12 hours and daily for 6 days. Using receiver‐operating characteristics curves, “statistically significant thresholds” established peak longitudinal changes for 8 biomarkers to differentiate mesothelioma patients who developed acute kidney injury (AKI) from normal healthy volunteers. We also assessed “medically significant thresholds” to differentiate mesothelioma patients who did vs. did not develop AKI. Statistically and medically significant thresholds for a fold‐change from baseline of urine creatinine (UCr)‐normalized values were established for 6 biomarkers: clusterin (2.2, 5.1); osteopontin (3.1, 7.1); N‐acetyl‐ß‐D‐glucosaminidase (2.7, 8.1); kidney injury molecule‐1 (4.3, 7.5); cystatin C (1.8, 4.5); neutrophil gelatinase‐associated lipocalin (2.9, 7.8). For urine albumin and total protein, thresholds were established based on UCr‐normalized absolute values: (> upper limit normal, > 10× upper limit normal). Statistically significant thresholds for all biomarkers outperformed eGFR at discriminating mesothelioma subjects exposed to cisplatin from healthy volunteers, demonstrating their utility for enhancing safe drug development. Medically significant thresholds provide perspective on when patients begin to exhibit AKI. These studies have established guideposts for confirmatory studies with additional cohorts and nephrotoxicants to formally qualify the selected biomarkers with worldwide regulatory authorities.
- 4 January 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (5) , 1272-1283
Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury
Two observational studies were conducted to support an initiative to qualify translational kidney safety biomarkers as clinical drug development tools that identify tubular injury prior to changes in estimated glomerular filtration rate (eGFR). Normal healthy volunteers provided three morning spot urine collections over 4 weeks. Patients undergoing surgical resection and intrathoracic cisplatin for malignant pleural mesothelioma provided urine samples pre‐ and postoperatively at 4, 8, and 12 hours and daily for 6 days. Using receiver‐operating characteristics curves, “statistically significant thresholds” established peak longitudinal changes for 8 biomarkers to differentiate mesothelioma patients who developed acute kidney injury (AKI) from normal healthy volunteers. We also assessed “medically significant thresholds” to differentiate mesothelioma patients who did vs. did not develop AKI. Statistically and medically significant thresholds for a fold‐change from baseline of urine creatinine (UCr)‐normalized values were established for 6 biomarkers: clusterin (2.2, 5.1); osteopontin (3.1, 7.1); N‐acetyl‐ß‐D‐glucosaminidase (2.7, 8.1); kidney injury molecule‐1 (4.3, 7.5); cystatin C (1.8, 4.5); neutrophil gelatinase‐associated lipocalin (2.9, 7.8). For urine albumin and total protein, thresholds were established based on UCr‐normalized absolute values: (> upper limit normal, > 10× upper limit normal). Statistically significant thresholds for all biomarkers outperformed eGFR at discriminating mesothelioma subjects exposed to cisplatin from healthy volunteers, demonstrating their utility for enhancing safe drug development. Medically significant thresholds provide perspective on when patients begin to exhibit AKI. These studies have established guideposts for confirmatory studies with additional cohorts and nephrotoxicants to formally qualify the selected biomarkers with worldwide regulatory authorities.
- 1 May 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 15 (10) , 533-536
Considerations for Drug Development Biomarker Assays in the Clinical Laboratory
- 1 May 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 15 (10) , 533-536
Considerations for Drug Development Biomarker Assays in the Clinical Laboratory
- Open Access
- 13 January 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 108, 105281
Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease
- 13 January 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 108, 105281
Open AccessPlasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease